AKT1 and early-onset autosomal dominant Alzheimer disease: The activation of the GPCR-mediated PI3K/Akt pathway is a recognized downstream event and a promising therapeutic target in neurodegenerative diseases such as Parkinson's (53) and Alzheimer's diseases (54).